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Abstract 
PARP1 (poly(ADP-ribose) polymerase 1) is a 
nuclear protein involved in the regulation of various 
biological processes including apoptosis, DNA 
repair for the maintenance of genome integrity, 
epigenetic marking of chromatin, assembly of 
higher-order chromatin structures, transcriptional 
activation, differentiation, proliferation, and cell 
cycle. Particularly, due to its decisive role in several 
DNA repair pathways, the inhibition of PARP1 has 
emerged as a prominent therapeutic option in cancer 
treatment, by improving the efficiency of 
chemotherapeutics or radiation therapy. 
Keywords 
PARylation, DNA repair, cancer, inflammation, 
neurodegenerative diseases, viral infections 
Identity 
Other names 
PARP-1, ADPRT, ARTD1, PPOL, ADP-
Ribosyltransferase NAD(+), Poly(ADP 
Ribosyl)Transferase, Poly(ADP-Ribose) 
Synthetase, EC 2.4.2., PADPRT-1, EC 2.4.2, 
ADPRT1, PARP 
HGNC (Hugo): PARP1 
Location: 1q42.12 
Local order 
Starts at 226360691 and ends at 226408093 
(GRCh38.p13 Assembly) (Figure 1). 
Note 
PARP1 has been found to be related with almost all 
the biological events and signalling pathways. 
Figure 1. Genomic location of human PARP1 (Chromosome 1 - NC_000001.11, GRCh38.p13 Assembly) 
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DNA/RNA 
Note 
The poly (ADP-ribose) polymerase (PARP) proteins 
have been characterized as enzymes that catalyse the 
attachment of the ADP-ribose subunits to itself and 
to multiple target proteins by using NAD+ as the 
substrate (Citarelli, Teotia, & Lamb, 2010; Ray 
Chaudhuri  Nussenzweig, 2017). This post-
transcriptional modification is called Poly(ADP-
ribosyl)ation (PARylation) (Citarelli et al., 2010). 
PARylation is a reversible modification: it is 
accomplished by the concerted actions of poly(ADP-
ribose) polymerase (PARP) enzymes and poly(ADP-
ribose) (PAR) hydrolysing enzymes such as PAR 
glycohydrolase (PARG) and ADP-ribosyl hydrolase 
3 (ADPRHL2) (Virág, Robaszkiewicz, Rodriguez-
Vargas,  Oliver, 2013).  The removal of terminal 
ADP-ribose unit is achieved by the hydrolytic 
activity of macrodomain proteins (MACROD1, 
MACROD2, and OARD1) (Perina et al., 2014).  
PARylation is a widely used process in eukaryotes. 
In eukaryotic species, the distribution of PARP 
proteins strictly follows the distribution of PARGs 
and at least one of the macrodomain proteins is also 
always present (Perina et al., 2014). On the other 
hand, PARP proteins are less common in bacteria 
and are thought to be acquired through horizontal 
gene transfer (Alemasova & Lavrik, 2019; Perina et 
al., 2014). In thermophilic archaeon Sulfolobus 
solfataricus, a protein with oligo(ADP-ribosyl) 
transferase activity was identified (Faraone-
Mennella, Gambacorta, Nicolaus,  Farina, 1998) and 
in a number of dsDNA viruses have also been found 
to possess PARP homologues (Perina et al., 2014).  
Based on the sequence homology, humans are  
assumed to express 17 defined PARPs (Vyas, 
Chesarone-Cataldo, Todorova, Huang, Chang, 
2013). PARP1, the first PARP purified and cloned 
from human, is a constitutive and the best studied 
member of the PARP family of proteins (Citarelli et 
al., 2010).  
The PARP1 gene is conserved in chimpanzee, 
Rhesus monkey, dog, cow, mouse, rat, chicken, 
zebrafish, fruit fly, mosquito, C.elegans, A.thaliana, 
rice, and frog (Table 1).  
 
Gene Species Gene Symbol Identity (%) DNA 
vs. P.troglodytes PARP1 99,2 
vs. M.mulatta PARP1 97,7 
vs. C.lupus PARP1 88,4 
vs. B.taurus PARP1 88,4 
vs. M.musculus Parp1 86,5 
vs. R.norvegicus Parp1 86,1 
vs. G.gallus PARP1 75,2 
vs. X.tropicalis parp1 72 
vs. D.rerio parp1 69,5 
vs. D.melanogaster Parp 49,5 
vs. A.gambiae AgaP_AGAP003230 53,1 
vs. C.elegans pme-1 48,2 
vs. A.thaliana PARP1 50,2 
vs. O.sativa Os07g0413700 51,7 
Table 1. Pairwise alignment of PARP1 gene (in distance 
from human) (HomoloGene:1222, NCBI). 
 
Description 
The PARP1 gene is a protein-coding gene. It is 
located at 1q42.12 on the minus strand and consists 
of 23 exons spanning ∼43 kb (starts at 226360691 
and ends at 226408093; GRCh38.p13 Assembly, 
NCBI). 
 
 
 
Figure 2. Display of human PARP1 gene transcript exons (Ensembl release 98 - September 2019) 
 
 
Name/Gene ID Description Location (bp) Aliases 
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PARP1P2 (ID: 
145) 
poly(ADP-ribose) polymerase 1 pseudogene 2  Chr 14, NC_000014.9 (63123001..63123935) 
ADPRTP2, 
PPOLP2 
PARP1P1 (ID: 
144) 
poly(ADP-ribose) +B7:D7polymerase 1 
pseudogene 1 
Chr 13, NC_000013.11 
(110936624..110940232) 
ADPRTP1, 
PPOLP1 
Table 2. Transcripts of human PARP1 gene (Ensembl release 98 - September 2019) 
 
 
Transcription 
This gene has 10 transcripts (splice variants) 
depending on Ensembl release 98 - September 2019 
(Table 2 and Figure 2).  
The human PARP1 promoter region does not contain 
typical regulatory elements, such as TATA or CAAT 
boxes.  
A near 40-base-pair region surrounding the 
transcription start site described as containing a near-
consensus initiator element capable of initiating 
RNA polymerase II transcription (Abbotts  Wilson, 
2017).  
Detailed analyses of the promoter regions of PARP1 
genes in humans, rats, and mice showed that PARP1 
promoter sequences have binding sites for 
transcription factors SP1, AP-2, YY1, ETS1, and 
NF1.  
In the distal promoter region of human PARP1 gene 
Candidate binding sites for several other factors 
including  CDE, KLF4 (GKLF), BARB, RRM1 
(MAZF), RREB1, HOX, GSX1 (GSH-1), CEBPB, 
NFIL3 (E4BP4), STAT6, cETSZ-1, PBX1, LEF1 
(TCF), NF-kB, REL, ZNF148 (ZBP-89), KLF6 
(CPBP), USF, CDF-1, EGR1, and IKZF1 (Ikaros 1) 
were also identified (Doetsch, Gluch, Poznanovic, 
Bode, & Vidakovic, 2012).  
Additionally, at the post-transcriptional level, miR-
124, MIR223, let-7a, miR-7-5p, and MIR125B2 
were shown to regulate cellular PARP1 expression 
(Dash et al., 2017; J. Lai et al., 2019; Wielgos et al., 
2017).  
Pseudogene 
There are two known pseudogenes of PARP1: 
PARP1P1 and PARP1P2 located on chromosomes 
13 and 14, respectively (Table 3). A germline, two-
allele (A/B) polymorphism of PARP1P1 on 
chromosome 13q34-qter has been identified. In the 
B-allele, a 193 bp deletion was determined and this 
deletion has been shown to be associated with cancer 
predisposition to multiple myeloma, monoclonal 
gammopathies, prostate cancer, and lung cancers in 
African Americans. On the other hand, more recent 
studies do not support the earlier findings which 
suggest that the PARP1P1 genotype plays a critical 
role in cancer susceptibility (Lockett, Snowhite, Hu, 
2005). Analyses, comprising a larger cohort that is 
selected based on case/control differences rather 
than racial/ethnic differences, are needed to clarify if 
there is any significant role of this pseudogene in 
cancer predisposition. 
Protein 
Note 
Encoded proteins by PARP1 gene in human are 
given in Table 4 and PARP1 protein similarity across 
species are given in Table 5.  
 
 
 
 
PARP1-201 ENST00000366790.3 570 - - Protein coding 
PARP1-202 ENST00000366792.3 553 - - Protein coding 
PARP1-203 ENST00000366794.10 3978 CCDS1554 NM_001618.4 Protein coding 
PARP1-204 ENST00000463968.5 830 - - lncRNA 
PARP1-205 ENST00000468608.1 438 - - lncRNA 
PARP1-206 ENST00000469663.1 542 - - lncRNA 
PARP1-207 ENST00000490921.5 3165 - - lncRNA 
PARP1-208 ENST00000491816.1 416 - - lncRNA 
PARP1-209 ENST00000498787.1 628 - - lncRNA 
PARP1-210 ENST00000629232.1 477 - - Protein coding 
Table 3. Pseudogenes of human PARP1 gene (GRCh38 Assembly, NCBI) 
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Name Transcript ID Protein Charge 
Isoelectric 
Point 
Molecular 
Weight 
CCDS UniProt RefSeq 
PARP1-
201 
ENST00000366790.3 155aa 10,0 9,4862 
 17,324.99 
g/mol 
- Q5VX85 - 
PARP1-
202 
ENST00000366792.3 108aa 3,0 7,7272 
 12,234.02 
g/mol 
- Q5VX84 - 
PARP1-
203 
ENST00000366794.10 1014aa 31,5 9,3322 
113,083.79 
g/mol  
CCDS1554 
A0A024R3T8 
P09874 
NM_001618.4 
PARP1-
210 
ENST00000629232.1 108aa 3,0 7,7272 
12,234.02 
g/mol  
- Q5VX84 - 
Table 4. Protein products of human PARP1 gene (Ensembl release 98 - September 2019
 
 
Gene Species Gene Symbol Identity (%) PROTEIN 
vs. P.troglodytes PARP1 99 
vs. M.mulatta PARP1 98,2 
vs. C.lupus PARP1 94,1 
vs. B.taurus PARP1 90,4 
vs. M.musculus Parp1 92,2 
vs. R.norvegicus Parp1 91,6 
vs. G.gallus PARP1 79,5 
vs. X.tropicalis parp1 75,7 
vs. D.rerio parp1 72,1 
vs. D.melanogaster Parp 43,8 
vs. A.gambiae AgaP_AGAP003230 46,5 
vs. C.elegans pme-1 41,1 
vs. A.thaliana PARP1 42,3 
vs. O.sativa Os07g0413700 42,7 
Table 5. Pairwise alignment of PARP1 protein sequences (in distance from human) (HomoloGene:1222, NCBI) 
 
 
 
 
Figure 3. Domain organization of PARP1:  ZF1-3: zinc finger domains 1-3; BRCT: BRCA1 C terminus domain; WGR: tryptophan-
glycine-arginine rich domain; PRD: PARP regulatory domain; ART: catalytic domain, highly-conserved in other ADP-ribosyl 
transferases; NLS: Nuclear Localization Signal. The figure is modified from (Abbotts Wilson, 2017). 
 
Description 
PARP1 encodes poly (ADP-ribosyl) transferase (EC 
2.4.2.30) (NCBI Homo sapiens Annotation Release 
109). Poly (ADP-ribose) polymerase1 (PARP1) is an 
isoform of the PARP enzyme family (Pacher Szabó, 
2007). Full length PARP1 protein comprises three 
major functional domains: an amino-terminal DNA-
binding domain, a carboxy-terminal catalytic 
domain (CD; also called as CAT), and a central auto 
modification domain (called as AMD or AD) 
(Altmeyer, Messner, Hassa, Fey, & Hottiger, 2009; 
Gross, Kotova, Maluchenko, Pascal, & Studitsky, 
2016). DBD contains two zinc finger domains 
(ZFI/ZF1 and ZFII/ZF2; also known as Zn1 and 
Zn2). Langelier et al. reported that the ZF2 domain 
exhibits high binding affinity to DNA compared to 
the ZF1 domain and Gradwohl et al. showed that 
disruption of the metal-binding ability of the ZF2 
dramatically reduces the binding to target DNA 
(Gradwohl et al., 1990). In addition, in both in vitro 
and in vivo, the ZF1 domain was found to be 
necessary for DNA-dependent PARP1 activity 
whereas the ZF2 domain was not required strictly 
(Langelier, Planck, Roy, & Pascal, 2011). An 
PARP1 (poly(ADP-ribose) polymerase 1) Tunçer S, Kavak K 
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additional zinc finger domain (ZFIII/ZF3; also 
known as Zn3) presents after DBD and it mediates 
inter-domain contacts, important for the PARP1 
activation. (Langelier et al., 2011; Tao, Gao, 
Hoffman, Liu, 2008). A bipartite nuclear localization 
signal (NLS) also lies in DBD and contains a caspase 
cleavage site DEVD214 (Castri et al., 2014). The 
AMD region is located in the central region of the 
enzyme and the region has acceptor amino acids for 
the covalent attachment of PAR. Moreover, a weak 
leucine-zipper motif has been described in the 
amino-terminal region of the AMD, which suggests 
that this motif may function in homo- and/or hetero-
dimerization. The AMD of PARP1 also includes a 
breast cancer 1 protein (BRCA1) C-terminus 
(BRCT) domain as well as an unstructured loop that 
connects the AMD with the PARP homology 
domain (Altmeyer et al., 2009). The carboxy-
terminal CD is the most conserved region across 
PARP family of proteins in different species. This 
domain has the 'PARP signature' characterized by 
NAD acceptor sites and critical residues involved in 
the initiation (the attachment of the first ADP-ribose 
moiety onto an acceptor amino acid), elongation (the 
addition of further ADP-ribose units onto already 
existing ones) and branching (the generation of 
branching points) of PAR (Altmeyer et al., 2009; 
Simonin et al., 1990). Followed by the CD, there is 
a WGR region, named after the identification of 
conserved amino acid sequence in the motif: 
Tryptophan-W, Glycine-G, Arginine-R. WGR 
region functions in DNA binding and inter-domain 
contacts essential for DNA damage-dependent 
activation (Altmeyer et al., 2009; Dawicki-McKenna 
et al., 2015; Langelier, Planck, Roy, Pascal, 2012). 
The domain organization of PARP1 is shown in 
Figure 3.  
PARP1 is known to be activated by mono-ADP-
ribosylation, acetylation, increased cellular calcium 
concentration, or by binding to tyrosyl tRNA 
synthase. On the other hand, self-PARylation and 
sumoylation were shown to inhibit PARP1 activity. 
PARP1 can also be phosphorylated in a reversible 
manner and the phosphorylation can activate (e.g., 
AMP-activated protein kinase [AMPK]) or inhibit 
(e.g., protein kinase C) PARP-1 activity (Bai, 2015). 
In addition, physical interactions with other proteins, 
including histones, HPF1, HMGN1, XPA, NEIL1, 
OGG1, DDB2, TP53, and MAPK1 (ERK2) found to 
regulate PARP1 activity (Alemasova  Lavrik, 2019). 
It was also reported that dimerization of PARP1 
enhances its enzymatic activity while further 
multimerization or dissociation to single PARP1 
molecules leads to decreased enzymatic activity 
(Alemasova  Lavrik, 2019). 
Expression 
PARP1 is an abundantly and ubiquitously expressed 
protein in most tissues (Schiewer & Knudsen, 2014). 
Compared to normal counterparts, enhanced PARP1 
expression is found in various types of tumors, but 
the most striking differences in PARP1 expression 
have been found in breast, ovarian, endometrial, 
lung, skin cancers and non-Hodgkin's lymphoma 
(Galia et al., 2012; Ossovskaya, Koo, Kaldjian, 
Alvares,  Sherman, 2010). 
Localisation 
PARP1 is primarily localized to the nucleus, but a 
distinct fraction was also detected in the 
mitochondria. Unlike nuclear PARP1, mitochondrial 
PARP1 has been shown to affect mitochondrial 
DNA repair negatively (Szczesny, Brunyanszki, 
Olah, Mitra, Szabo, 2014).  
PARP1 is one of several known cellular substrates of 
CASP3 and CASP7 (caspase 3 and caspase 7) and 
cleavage of PARP1 by these caspases is considered 
to be a hallmark of apoptosis. Upon cleavage, two 
specific fragments of PARP1 are generated: an 89 
kDa fragment containing AMD and the catalytic 
domain of the enzyme and a 24 kDa containing 
DBD. The 89 kDa fragment has a greatly reduced 
DNA binding capacity and is liberated from the 
nucleus into the cytosol. On the other hand, the 24 
kDa cleaved fragment with 2 zinc-finger motifs does 
not leave the nucleus where it binds to nicked DNA 
irreversibly and therefore acts as a trans-dominant 
inhibitor of active PARP1 (Chaitanya, Alexander,  
Babu, 2010). 
Function 
ADP-ribosylation is a posttranslational 
modification.  By using the oxidized form of NAD+ 
as a substrate, PARP enzymes bind and cleave NAD+ 
to nicotinamide (NAM) and ADP-ribose (ADPR) 
and catalyze the covalent binding of ADPR units 
onto glutamate, aspartate, tyrosine, lysine, and serine 
residues of target proteins (Rodrèguez-Vargas, 
Oliver-Pozo, & Dantzer, 2019). PARP1, PARP2, 
tankyrase 1 (TNKS), and tankyrase 2 (TNKS2) 
synthesize branched PAR polymers and the 
remaining PARP enzymes are either mono or oligo 
ADPR-transferases. No enzymatic activity has been 
identified for ZC3HAV1 (PARP13) (Bai, 2015). 
PARP1 is the prototype member of the PARP family 
of enzymes and more than 80% of stimulated and 
basal cellular PARP activity are exerted by PARP1 
(Bai, 2015; Rajamohan et al., 2009).  
Although PARP1 has been long defined as a DNA-
damage response protein, recent investigations 
highlight multiple functions of PARP1 including 
transcription, replication, aging, viral protection, cell 
cycle regulation, modification of chromosome 
structure, differentiation,  inflammation, metabolic 
regulation, proteasomal degradation, and RNA 
processing (Bai, 2015; Rodrèguez-Vargas et al., 
2019) (Figure 4).  
PARP1 functions in DNA repair  
PARP1 (poly(ADP-ribose) polymerase 1) Tunçer S, Kavak K 
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Genotoxic stress results in various types of DNA 
lesions, including DNA single-strand breaks (SSBs) 
and double-strand breaks (DSBs). If not repaired, 
accumulated damage can disrupt genomic integrity. 
Fortunately, cells have evolved different DNA-
damage repair responses that repair these DNA 
lesions to insure genomic stability (C. Liu, Vyas, 
Kassab, Singh, Yu, 2017).  
PARP1 recognizes both SSBs and DSBs and 
transfers the ADP-ribose moiety of NAD+ to the side 
chains of asparagine, aspartic acid, glutamic acid, 
arginine, lysine, serine and cysteine residues on its 
target proteins. Through their PAR-binding 
domains, these PAR chains form a platform and 
recruit DNA repair proteins. Therefore, PARP1 is an 
important DNA damage sensor for both SSBs and 
DSBs (Ray Chaudhuri Nussenzweig, 2017).  
PARP1 modulates chromatin structure and 
transcription  
PARP1 functions in chromatin compaction, 
decondensation and it modulates epigenetic marks 
via PARylating histones and chromatin remodeling 
enzymes (Quénet, El Ramy, Schreiber,  Dantzer, 
2009). Being as a component of enhancer/promoter-
binding complexes, besides its effects on chromatin 
structure, PARP1 can bind to most of the RNA 
polymerase II transcribed genes and mediate around 
3.5% of all transcribed RNAs covering a broad range 
of functions from inflammation to metabolism (Ke, 
Zhang, Lv, Zeng, & Ba, 2019; Kraus, 2008). PARP1 
can also enhance the accessibility of promoters via 
histone and nucleosome replacements and can 
enhance transcription by replacing negative 
transcriptional cofactors with positive ones (Kraus & 
Hottiger, 2013; Muthurajan et al., 2014).  
Recent findings described new roles of PARP1 in the 
regulation of RNA binding proteins, rRNA 
synthesis, ribosome biogenesis, and mRNA 
regulation (Ke et al., 2019; Ryu, Kim, Kraus, 2015). 
Accordingly, PARP1 can regulate gene expression at 
the post-transcriptional level.  
Cell death and PARP1  
As mentioned before, PARP1 is known to be cleaved 
and inactivated by active caspases 3 and 7 and this 
cleavage is accepted as a 'hallmark of apoptosis' 
(Castri et al., 2014; Desroches & Denault, 2019). 
The cleavage causes the formation of 24 kDa and 89 
kDa fragments. Depending on the intensity and type 
of stimuli resulting in the cleavage, two main 
consequences have been reported: (1) reduced 
PARylation during DNA repair processes; (2) the 
modification of PARP1 transcriptional activity 
(Castri et al., 2014).  
Recent studies indicate that PARP1 hyperactivation, 
ie. excessive PARylation by PARP1,  can lead 
'parthanatos', a form of necrotic cell death which 
PAR induces the nuclear translocation of apoptosis-
inducing factor ( AIFM1) from mitochondria to 
initiate chromatinolysis and cell death independently 
of caspase activation. For a long time, it has been 
thought that the cell death caused by excessive 
activation of PARP occurs via the catalytic 
consumption of NAD+ followed by ATP reduction 
and bioenergetic collapse. However, Andrabi et al. 
showed that not the decreased NAD+, but PAR-
dependent inhibition of hexokinase activity leads to 
defects in glycolysis and therefore causes the 
bioenergetic collapse. On the other hand, PARP1 
activity is kept at much lower levels during normal 
unstressed cellular conditions (Andrabi et al., 2014; 
Dawicki-McKenna et al., 2015; Gupte, Liu, Kraus, 
2017). 
Figure 4. Multifaceted nature of PARP-1:  PARP1 functions in DNA repair, chromatin modification, inflammation, transcriptional 
regulation, and cell death. DBS: Double Strand Break; BER: Base Excision Repair; SSB: Single Strand Break; SPR: Short-Patch 
Repair; LPR: Long-Patch Repair. The figure is modified from (Swindall, Stanley, Yang, 2013). 
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Figure 5. The Role of PARP1 in human organs.  The figure is modified from (Bai, 2015). 
 
Mutations 
Note 
A list of PARP1 mutations in cancer can be found in: 
COSMIC, the Catalogue of Somatic Mutations in 
Cancer, 
https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln
=PARP1 
Germinal 
Parp1-/- mice are viable, fertile, normal in size and do 
not display any gross physical or behavioral 
abnormalities (Tha Jackson Laboratory; 
www.jax.org/strain/002779). 
Somatic 
Lys933Asn and Lys945Asn mutations were found to 
be significantly correlated with colorectal cancer 
(CRC) in the Saudi population.  Since these 
mutations were identified to be localized in PARP1 
catalytic domain (CD), mutations of these lysine 
residues were suggested to affect the PARP1 
catalytic activity (Alshammari, Shalaby, Alanazi, 
Saeed, 2014).  
In addition, Val762Ala polymorphism in the CD has 
been reported as the most common variant of PARP1 
associated with an increased risk of many tumors 
(Toss Laura, 2013).  
Using genome-wide and high-density CRISPR-Cas9 
'tag-mutate-enrich' mutagenesis screens, Pettitt et al. 
identified PARP1 mutant alleles that cause in vitro 
and in vivo PARP inhibitor resistance. The results 
reveal that point mutations in the ZnF domains were 
sufficient for the inhibitor resistance (Pettitt et al., 
2018).  
Polymorphisms: In addition to mutations, through 
modulation of PARP1 expression level and enzyme 
activity, PARP1 gene polymorphisms can affect the 
outcome and response to therapy of cancer. For 
example, PARP1 SNP rs1805407, found in perfect 
linkage disequilibrium with two PARP1 promoter 
SNPs (rs2077197 and rs6665208), was shown to be 
associated with higher PARP1 expression 
(Abecassis et al., 2019).  In another study, expression 
quantitative trait locus (eQTL) analysis in 
melanocytic cell types revealed that presence of the 
1q42.1 melanoma risk allele (rs3219090[G]) is 
correlated with higher PARP1 levels. Furthermore, a 
proteomic screen identified that RECQL helicase 
binds to the insertion allele of PARP1 (indel SNP 
rs144361550) in melanoma cells and primary human 
melanocytes (J. Choi et al., 2017). In another study, 
using a new data integrative approach applied on 
multi-modal -omics, and clinical data, Abecassis et 
al. demonstrated that response to chemotherapy is 
directly linked to the gene expression, four 
methylation variables and PARP1 SNP rs1805407 in 
a cohort of metastatic melanoma patients (Abecassis 
et al., 2019). According to the results of another 
genotyping study, Val762Ala, Asp81Asp, and 
Lys352Lys polymorphisms and the haplotype-
ACAAC in PARP1 are associated with reduced risk 
PARP1 (poly(ADP-ribose) polymerase 1) Tunçer S, Kavak K 
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of non-Hodgkin lymphoma in Korean males (Jin et 
al., 2010). In a case-control study conducted in the 
Hexi area of China, PARP1 2819G allele was shown 
to be associated with an increased risk of gastric 
cancer (He, Liu, Shan, Zhu, Li, 2012).  
In addition, PAR metabolism is also involved in 
malignancies. For instance, PARylation of proteins 
in peripheral blood leukocytes was shown to be 
reduced by more than 50% in head, neck, breast and 
cervical cancers (Lakadong, Kataki, Sharan, 2010). 
Implicated in 
PARP1 has been implicated in several human 
pathologies (Figure 5). Defects in PARP1 function 
have been shown to be associated with several 
diseases, such as conditions or diseases related with 
chronic inflammation, neurodegenerative disorders, 
cardiovascular diseases, and cancer. 
Cardiovascular diseases 
Myocardial infarction (MI) is a common 
cardiovascular disease characterized by the 
induction of inflammation and apoptosis of 
cardiomyocytes because of the diminished levels of 
oxygen and nutrients in the myocardial tissue. In a 
rat model of MI, Wang et al. suggested that oxidative 
DNA damage caused by the generation of reactive 
species during the onset of MI can cause excessive 
activation of PARP1 followed by an imbalance of 
cell survival mechanisms that contribute to the death 
of cardiomyocytes. The authors showed that 
inhibition of iNOS (Inducible nitric oxide synthase), 
an important member of inflammatory cytokines 
regulated by PARP1 via the NF- kB pathway, or 
inhibition of PARP1 was able to reduce the level of 
apoptosis caused by the ischemic myocardial 
damage (J. Wang et al., 2015).  
More recently, it has been shown that PARP1 can 
affect cardiac functions also via autophagy 
activation. Therefore, inhibition of PARP1 was 
suggested to be protective against cardiac ischemia 
injury by repressing autophagy (C. Wang, Xu, 
Zhang, Zhang, Huang, 2018). 
Diabetes and Obesity 
PARP1 has been suggested to play an important role 
in adipogenesis and cellular metabolism (Erener, 
Hesse, Kostadinova, & Hottiger, 2011; Jokinen, 
Pirnes-Karhu, Pietiläinen, & Pirinen, 2017; Luo et 
al., 2017). In their in vivo study, Devalaraja-
Narashimha and Padanilam showed that knock out 
of Parp reversed resistance to diet-induced obesity 
by decreasing energy expenditure in mice 
(Devalaraja-Narashimha Padanilam, 2010). 
Central Nervous System Disorders 
PARP1 activation is known to be associated with the 
pathogenesis of several central nervous system 
disorders, including ischemia, neuroinflammation, 
and neurodegenerative diseases such as Parkinson's 
disease (PD), Amyotrophic lateral sclerosis (ALS) 
and Alzheimer's disease (AD) (Martire, Mosca, & 
d'Erme, 2015; Palazzo, Mikolcevic, Mikoc, Ahel, 
2019). Neurological disorders can be characterized 
by aggregation of cytotoxic proteins, enhanced 
levels of oxidative stress followed by DNA damage, 
PARP1 activation, and excess of cellular levels of 
PAR (Palazzo et al., 2019). For instance, in PD, 
intracellular monomericSNCA (alpha-synuclein) 
forms higher-ordered protein aggregates which can 
spread from cell to cell. These α-synuclein 
aggregates can activate nitric oxide synthase which 
enhances the production of NOS. NOS can cause 
DNA damage and activation of PARP1 and nuclear 
production of PAR. PAR is transported into the 
cytosol where it interacts with α-synuclein and 
further accelerates fibrillization and misfolding of 
this cytotoxic protein α-synuclein in a pathogenic 
loop. Ultimately, accumulation of pathologic α-
synuclein results in cell death via parthanatos and 
neuronal dysfunction (Kam et al., 2018).  
A growing number of evidence shows that 
mitochondrial function is strictly controlled by 
PARP1 which is responsible for about more than 
90% of PARylation in the brain (Pieper et al., 2000). 
In addition to oxidative stress which is able to 
activate PARP1, recent studies claim that PARP1 is 
a critical component of a molecular interactions 
network responsible in the nervous system disorders 
related to mitochondrial function. It was suggested 
that deleterious consequences of PARP1 activation 
on mitochondrial function are caused by its 
interaction with SIRT1 (Sirtuin 1). In addition, the 
interaction of PARP1 with promoters of nuclear 
genes encoding for mitochondrial transcription 
factors and mtDNA repair proteins were identified 
(Czapski et al., 2018). 
Viral Infections 
A broad range of DNA and RNA viruses are known 
to activate DNA repair pathways in the absence of 
host DNA damage. PARP1 is known to be recruited 
to the Kaposi's sarcoma-associated herpesvirus and 
Epstein-Barr virus genomes and it prevents viral 
replication by modifying viral proteins involved in 
genome replication and partitioning. On the other 
hand, hepatitis B virus was found to require PARP1 
for efficient transcription. Additionally, PARP1 
inhibits the expression of retrotransposons in 
Drosophila and retroviruses in avian cells (Gutierrez, 
Valdes, Serguera, & Llano, 2016). It has been 
reported that efficient HIV-1 (Human 
Immunodeficiency Virus-1) integration and 
transcriptional activation also require PARP1 
activity (Ha et al., 2001; Yu, Liu, Yang, & Zhou, 
2018). Recently, PARP1 was shown as a cofactor in 
the activity of the influenza A virus polymerase 
(Westera et al., 2019). In another study, Shou et al. 
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showed that PARP1 functions as a regulator of NF-
kB by promoting its nuclear translocation and by 
facilitating its binding to the NF-kB response 
sequences in macrophages upon vaccinia virus 
infection; therefore PARP1 can provide viral control 
through natural killer (NK) cell recruitment to the 
site of infection (Shou, Fu, Huang,  Yang, 2019) 
Gastric cancer 
Depending on the survival analysis, upregulation of 
PARP1 expression was shown to be correlated with 
poor overall survival rates of gastric cancer patients 
(Afzal et al., 2019). Enhanced PARP1 expression 
was found to be significantly associated with 
Helicobacter pylori infection, decreased 
differentiation, increased depth of invasion, presence 
of lymphatic invasion and lymph node metastasis, 
and advanced tumor-node-metastasis stage (Y. Liu 
et al., 2016). 
Lung cancer 
In lung adenocarcinoma patients, PARP1 was 
claimed to enhance tumor metastasis through 
supporting several metastatic features, including 
anoikis resistance, invasion, extravasation and self-
renewal (E. B. Choi et al., 2016). 
Ovarian cancer and Breast cancer 
Breast Cancer Susceptibility Genes BRCA1 and 
BRCA2 are tumor suppressors that function in the 
repair DSBs via the homologous recombination 
(HR) repair pathway. In BRCA mutant tumor cells, 
PARP inhibition was shown to induce 'synthetic 
lethality' resulting in profound tumor cell 
cytotoxicity without harming normal cells (Jiang, Li, 
Li, Bai, Zhang, 2019).  
In addition to malignant tissues of BRCA-mutant, 
triple-negative, and receptor-positive breast 
carcinoma, PARP1 is overexpressed significantly in 
uterine carcinoma and ovarian carcinoma. As in 
breast carcinoma, ovarian cancer cells show high 
sensitivity to drugs designed for PARP1 inhibition 
(Iqbal et al., 2012; Thompson & Easton, 2003; L. 
Wang et al., 2017). 
Pancreatic cancer 
BRCA2 mutation carriers have a more than 3 fold 
risk of developing pancreatic cancer and women 
with BRCA 1/2 mutation were shown to have an 
approximate 2.5 fold increase in the incidence of 
pancreatic cancer (Breast Cancer Linkage 
Consortium, 1999; Iqbal et al., 2012; Thompson  
Easton, 2003). In the context of familial pancreatic 
cancer, studies have shown that pedigrees with 
germline mutations in BRCA1 and BRCA2 have an 
increased lifetime risk of pancreatic cancer. A 
germline mutation in one of these genes represents 
the earliest risk factor in many familial pancreatic 
cancer kindreds. In patients with sporadic pancreatic 
cancer, BRCA1/2 were also found to be mutated in 
the most advanced pancreatic intraepithelial 
neoplasia lesions (Greer & Whitcomb, 2007). In 
BRCA1/2 mutated tumors, which homologous 
recombination ca not be utilized to repair DSBs, 
inhibitors of PARP are suggested to target tumor 
cells to terminate their BER rescue pathway thus 
leading to accumulation of DNA damage, genomic 
instability and eventually cell death (Fogelman et al., 
2011; Yuan, Liao, Hsueh,  Mirshahidi, 2011). 
Non-Hodgkin's lymphoma 
PARP1 expression is known to be enhanced in non-
Hodgkin's lymphoma (Ossovskaya et al., 2010). 
Diffuse large B cell lymphoma (DLBCL) is the most 
common subtype of non-Hodgkin's lymphoma. 
Expression of LIM-domain only 2 (LMO2) is one of 
the best prognostic markers of longer survival 
following therapy. Very recently, LMO2 expression 
was found to lead dysfunction in homolog 
recombination (HR) and tumor cell sensitization to 
genotoxic agents and PARP1/2 inhibitors were 
shown to enhance this effect further. Therefore, 
Parvin et al. suggested that the utilization of PARP 
inhibitors in combination with 
immunochemotherapy in LMO2-expressing tumors 
such as DLBCL, follicular lymphoma, and T-ALL 
(Parvin et al., 2019).  
BCL6 is one of the therapeutic targets in lymphoma. 
As a transcription factor, BCL6 is expressed in 
germinal centre B cells and it is fundamental for the 
formation of germinal centres and the production of 
high-affinity antibodies. On the other hand, during 
terminal differentiation to plasma cells, BCL6 has to 
be transcriptionally downregulated. BCL6 is known 
to be highly expressed in B cell non-Hodgkin's 
lymphoma and in a subset of cases of diffuse large 
cell lymphoma. PARP1 was shown to bind in a 
sequence-specific manner at the BCL6 locus and 
contributes to the regulation of BCL6 transcription 
(Ambrose, Papadopoulou, Beswick, Wagner, 2007). 
Melanoma 
Melanoma is characterized by defects in repair and 
cell cycle regulation. Malfunctioning in nucleotide 
excision repair is thought to play an important role 
in melanoma. Since BRCA2 mutations are known to 
be associated with melanoma, PARP inhibitors were 
introduced into melanoma therapy. However, use of 
PARP inhibitors in melanoma therapy ended with 
controversial clinical observations. In an in vitro 
melanoma model, Cseh et al. showed that 
pharmacologic PARP inhibition triggers 
mitochondrial events known to be associated with 
cell survival, but also enhances the cytotoxic effects 
of cytostatic compounds (Cseh et al., 2019). These 
findings may explain the controversial results about 
the use of PARP inhibitors in the treatment of 
malignancies. 
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Colorectal cancer 
Colitis is the inflammation of the inner lining of the 
colon caused by several inflammatory factors like 
infection, ischaemia, and allergic reactions. Chronic 
inflammatory disorders, including inflammatory 
bowel diseases, Crohn's disease (CD) and ulcerative 
colitis (UC), are thought to result from a 
dysregulated mucosal immune response to 
commensal gut microbiota in genetically susceptible 
individuals. Colorectal cancer (CRC) is well known 
to be associated with long-standing and extensive 
colitis (Palazzo et al., 2019). PARP1 is 
overexpressed in human CRC and elevated PARP1 
expression is correlated with disease progression. 
Although PARP1 has been reported to support the 
focal inflammation during the tumor progression, 
protective effects of PARP1 against DNA alkylation 
and oxidation damage during the initial steps of CRC 
have also been shown. Mechanistically, the pro-
inflammatory functions of PARP1 were shown to be 
related with the modulation of NF-kB activity and 
stimulation of IL6-STAT3-cyclin D1 axis (Dörsam 
et al., 2018). 
Prostate cancer 
n vivo and in vitro studies showed that PARP1 can 
modulate androgen receptor ( AR) functions by 
recruiting to the AR function sites, and therefore by 
promoting AR occupancy and AR functions 
(Schiewer et al., 2012).  
Silencing of PARP1 was reported to downregulate 
epithelial-mesenchymal transition (EMT) markers, 
inhibit PI3K, suppress the expression of EGFR and 
p-GSK3B (Ser9) in in vivo and in vitro prostate 
cancer models (Y. Lai et al., 2018). 
To be noted 
The design of PARP1 inhibitors and clinical trials of 
PARP1 inhibitors in cancer have been receiving 
considerable attention. 
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